Nurix ended its fiscal year with an estimated, unaudited $609.6 million in cash and investments as of November 30, 2024.* Based on its operating plan, Nurix anticipates that the company will be able to fund its operating activities into the first half of 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics receives U.S. FDA Fast Track designation for NX-5948
- Nurix Therapeutics price target raised to $35 from $30 at H.C. Wainwright
- Nurix Therapeutics initiated with a Buy at BTIG
- Nurix Therapeutics Reports Promising Trial Results for NX-5948
- Nurix Therapeutics holds a pharmaceutical update conference call
Questions or Comments about the article? Write to editor@tipranks.com